- Addex Provides Corporate Update and Financial Guidance
- Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration
- Addex Reports Q3 2022 Financial Results and Provides Corporate Update
- Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022
- Addex Increases Issued Share Capital to Create Treasury Shares
- Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders
- Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022
Addex Therapeutics Ltd (ADXN:NAQ) closed at 1.44, 161.82% above the 52 week low of 0.55 set on Dec 22, 2022.
0.55Dec 22 20226.24Feb 25 2022
Markit short selling activity
|Market cap||25.90m USD|
Data delayed at least 15 minutes, as of Feb 03 2023 21:00 GMT.